Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2

Conditions

Uterine Cervical Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Penile Neoplasms 2Oropharyngeal Neoplasms 2Anus Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

aldesleukin 2Adoptive Transfer 2trastuzumab deruxtecan 1talazoparib 1liposomal doxorubicin 1fludarabine 1dostarlimab 1belzutifan 1apixaban 1Vaccines, Synthetic 1Therapeutic Touch 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Specimen Handling 1Rivaroxaban 1Radiotherapy 1Radiation 1Papillomavirus Vaccines 1Paclitaxel 1Observation 1Nivolumab 1Magnetic Resonance Spectroscopy 1Imiquimod 1Hysterectomy 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Heparin, Low-Molecular-Weight 1Gemcitabine 1Fluorodeoxyglucose F18 1FAPI-46 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Vaginal Neoplasms × Adoptive Transfer × Clear all
NCT05639972 2026-02-27

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Rutgers, The State University of New Jersey

Phase 1/2 Recruiting
15 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT05686226 2026-02-27

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Rutgers, The State University of New Jersey

Phase 2 Recruiting
20 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡